HomeAFX • FRA
Carl Zeiss Meditec AG
€56.00
Dec 4, 9:57:40 AM GMT+1 · EUR · FRA · Disclaimer
StockDE listed securityDE headquartered
Previous close
€55.60
Day range
€55.50 - €56.00
Year range
€54.60 - €123.00
Market cap
5.12B EUR
Avg Volume
231.00
P/E ratio
24.58
Dividend yield
1.96%
Primary exchange
ETR
CDP Climate Change Score
B
In the news
Financials
Income Statement
Revenue
Net income
(EUR)Jun 2024Y/Y change
Revenue
539.34M0.79%
Operating expense
238.78M11.27%
Net income
34.13M-62.96%
Net profit margin
6.33-63.24%
Earnings per share
0.43
EBITDA
60.11M-43.58%
Effective tax rate
32.31%
Total assets
Total liabilities
(EUR)Jun 2024Y/Y change
Cash and short-term investments
15.34M24.06%
Total assets
Total liabilities
Total equity
2.11B
Shares outstanding
89.74M
Price to book
2.38
Return on assets
Return on capital
6.08%
Net change in cash
(EUR)Jun 2024Y/Y change
Net income
34.13M-62.96%
Cash from operations
Cash from investing
Cash from financing
Net change in cash
Free cash flow
About
Carl Zeiss Meditec AG is a multinational medical technology company and subsidiary of Carl Zeiss AG. It manufactures tools for eye examinations and medical lasers as well as solutions for neurosurgery, dentistry, gynecology and oncology. Among its products are the most common tools used by ophthalmologists and optometrists. In October 2018, Carl Zeiss Meditec won FDA premarket approval for its ReLEx Smile laser system. Also in October 2018, Carl Zeiss Meditec announced the acquisition of Reno, Nevada-based IanTech for an undisclosed sum. In September 2019, Carl Zeiss Meditec launched the CIRRUS 6000 at the European Society of Retina Specialists 2019 Congress. Wikipedia
Founded
2002
Employees
4,950
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu